Daily Cardiology Research Analysis
Analyzed 97 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out: a large-scale peptidomic atlas in heart failure that identifies bioactive peptide signals linked to outcomes; a nationwide cohort showing distinct incidence trends and risk profiles for STEMI versus NSTEMI in type 1 diabetes; and a translational porcine study demonstrating 24-hour hypothermic oxygenated perfusion preserves heart graft function after DCD and DBD procurement. Together, they advance molecular phenotyping, refine risk assessment, and expand transplant logistics.
Research Themes
- Molecular phenotyping and peptide biomarkers in heart failure
- Myocardial infarction subtypes and risk stratification in type 1 diabetes
- Organ preservation technologies for heart transplantation
Selected Articles
1. Decoding the Heart Failure Peptidome.
A cross-sectional mass spectrometry study quantified 21,694 plasma peptides in 486 heart failure patients and 98 controls, identifying 1,924 differentially expressed peptides and 65 peptides independently associated with outcomes. Machine learning-guided ranking and clustering revealed bioactive candidates (e.g., angiotensin-related and natriuretic peptide clearance receptor fragments) and three patient clusters, the worst survival characterized by inflammatory peptide signatures.
Impact: This study establishes a comprehensive HF peptidomic atlas with outcome-linked peptide signals, offering mechanistic and biomarker leads beyond traditional protein assays.
Clinical Implications: While not practice-changing yet, peptide signatures could inform future diagnostic panels, risk stratification, and therapeutic targeting (e.g., RAAS-related and natriuretic peptide clearance pathways).
Key Findings
- Quantified 21,694 plasma peptides; 1,924 were differentially expressed in HF versus controls.
- Machine learning prioritized 141 peptides (top 5%), with 65 independently associated with clinical outcomes.
- Three HF patient clusters emerged; the worst-survival cluster showed peptide patterns linked to acute phase response and inflammation.
- High-ranking candidates included angiotensin 1-9 and fragments mapping to the natriuretic peptide clearance receptor.
Methodological Strengths
- Large-scale, unbiased mass spectrometry with rigorous peptide quantification.
- Integrated ranking strategy combining regulation, bioactivity pattern similarity, and outcome association.
Limitations
- Cross-sectional design limits causal inference.
- External validation and assay standardization are needed before clinical translation.
Future Directions: Validate peptide panels in prospective cohorts, develop targeted assays, and test mechanistic roles of prioritized peptides in experimental models.
BACKGROUND: Peptides such as angiotensin II and brain natriuretic peptide are pivotal in diagnosing and treating heart failure (HF). However, unbiased systematic studies of the peptidome in patients with HF are lacking. Deciphering the plasma peptidome might significantly improve the diagnosis, prognostication, and treatment of patients with HF. METHODS: To systematically explore the low molecular peptidome, we conducted a cross-sectional mass spectrometry analysis from 486 patients with HF and 98 age-matched non-HF controls. We quantified 21 694 unique peptides in plasma, which were ranked according to (1) the relative upregulation in HF versus controls, (2) pattern similarity to bioactive peptides by an adapted machine learning method, and (3) association with clinical outcome. RESULTS: We observed 1924 differentially expressed peptides between patients with HF and non-HF controls. Among high-ranking peptides in patients with HF were angiotensin-related peptides (eg, angiotensin 1-9), propeptides from GIP (gastric inhibitory polypeptide), osteocalcin and cholecystokinin, and peptides mapping to the extracellular part of the natriuretic peptide clearance receptor and integrin alpha-7. Among the regulated peptides, 141 were scored in the top 5% by our machine learning approach, and 65 peptides herein were independently associated with clinical outcome. A hierarchical clustering analysis of patients with HF revealed 3 major patient clusters based on the peptide signature. The patient cluster with the lowest survival probability exhibited a specific peptide degradation pattern with a higher proportion of peptides linked to the acute phase response and increased inflammation. CONCLUSIONS: This study uniquely identifies peptides according to their regulation and likelihood of being a bioactive peptide in patients with HF compared with non-HF controls. The study provides crucial peptide-level information to complement protein-based methodologies. The most promising peptides were related to the renin-angiotensin system, natriuretic peptides, and cardiometabolic regulation. The stepwise ranking highlights the HF peptide signal important for outcome and provides a rich resource for additional exploration.
2. Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study.
In 4,215 adults with type 1 diabetes followed in the FinnDiane study, 20-year cumulative MI incidence was 15.4% (STEMI 2.4%, NSTEMI 10.9%). STEMI incidence declined over time, whereas NSTEMI increased after an initial decline. NSTEMI risk associated with dyslipidemia, microvascular disease, and kidney replacement therapy; in contrast, reduced eGFR predicted STEMI, highlighting distinct pathobiology and implications for targeted prevention.
Impact: Differentiating STEMI and NSTEMI epidemiology and risk determinants in type 1 diabetes refines risk assessment and can guide subtype-specific prevention and surveillance.
Clinical Implications: Risk management in type 1 diabetes should consider subtype-specific profiles: intensify lipid control and microvascular surveillance for NSTEMI risk, and monitor kidney function declines for STEMI risk; surveillance strategies may need to adapt to the observed temporal trends.
Key Findings
- Over 20 years, cumulative MI incidence was 15.4% (STEMI 2.4%, NSTEMI 10.9%) with no sex differences but strong age dependency, especially for NSTEMI.
- STEMI incidence declined across calendar time; NSTEMI increased after an initial decline.
- NSTEMI risk was associated with higher LDL, lower HDL, severe retinopathy, severe albuminuria, and kidney replacement therapy; reduced eGFR predicted STEMI.
- Findings support distinct risk pathways for STEMI versus NSTEMI in type 1 diabetes.
Methodological Strengths
- Prospective, multicentre nationwide cohort with adjudicated events and competing-risk modeling.
- Subtype-specific incidence and risk profiling using standardized and robust statistical methods.
Limitations
- Observational design with potential residual confounding.
- Generalizability may be limited to similar healthcare systems and populations.
Future Directions: Test targeted prevention strategies by MI subtype in type 1 diabetes and integrate dynamic risk models that incorporate renal and microvascular disease trajectories.
BACKGROUND: The incidence and risk profiles of ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) are understudied in type 1 diabetes. We aimed to study the similarities and differences in the incidence and risk profiles of myocardial infarction subtypes in people with type 1 diabetes. METHODS: This prospective, multicentre cohort, the FinnDiane Study includes adults with type 1 diabetes, with no previous history of myocardial infarction or coronary revascularisation. Standardised age-specific, sex-specific, and complication-specific incidence rates of myocardial infarction subtypes STEMI and NSTEMI were calculated in Fine and Gray competing risk analyses. The risk profiles were assessed with Cox regression and Fine and Gray competing risk models. FINDINGS: 4215 adults with type 1 diabetes who were enrolled in the Finnish Diabetic Nephropathy Study between Nov 21, 1997, and Dec 31, 2012, were included in this study. We verified 449 first-ever clinically recorded myocardial infarctions, including 84 (19%) STEMIs and 297 (66%) NSTEMIs, from medical records and death certificates between 1997 and 2017. The 20-year cumulative incidence was 15·4% (95% CI 12·0-19·1) for all myocardial infarctions, 2·4% (1·9-2·9) for STEMI, and 10·9% (7·8-14·6) for NSTEMI, with no differences by sex, but increasing with older age, particularly for NSTEMI. Compared with the reference period between 1997 and 2002, the incidence of STEMI decreased, while after an initial decline, NSTEMI incidence increased during follow-up. Older diabetes onset age, increased LDL cholesterol, reduced HDL cholesterol, severe diabetic retinopathy, severe albuminuria, and kidney replacement therapy were associated with increased risk of NSTEMI, but not of STEMI. Conversely, moderately and severely decreased eGFR were associated with increased risk of STEMI, but not of NSTEMI. Longer duration of diabetes, higher HbA INTERPRETATION: We report that STEMI and NSTEMI exhibit different incidence patterns depending on age and year of myocardial infarction. STEMI and NSTEMI also differed regarding risk profiles, demonstrating that myocardial infarction risk assessment involves a complex interplay between multiple risk factors in type 1 diabetes. FUNDING: Folkhälsan Research Foundation, Wilhelm and Else Stockmann Foundation, Liv och Hälsa Society, Sigrid Jusélius Foundation, State funding for university-level health research by Helsinki University Hospital, Medical Society of Finland, Diabetes Research Foundation, and Finnish Foundation for Cardiovascular Research.
3. Twenty-Four-Hour Hypothermic Oxygenated Perfusion Preserves Graft Viability in a Porcine DCD and DBD Heart Transplant Model.
In a porcine transplant model using 8 DCD and 8 DBD hearts, 24-hour hypothermic oxygenated perfusion preserved graft function, enabling successful CPB weaning with comparable cardiac outputs (≈5.0 vs 4.5 L/min). LV contractility (Ees) improved versus baseline and no primary graft dysfunction occurred during 2-hour observation, supporting the feasibility of markedly extending preservation times.
Impact: Demonstrating 24-hour preservation with preserved biventricular function in both DCD and DBD hearts could transform logistics, expand donor pools, and enable longer transport/coordination windows.
Clinical Implications: If replicated in humans, HOPE could extend safe ischemic times, improve organ allocation efficiency, and reduce discard rates, particularly for DCD hearts; clinical trials are warranted.
Key Findings
- Twenty-four hours of hypothermic oxygenated perfusion preserved graft viability in both DCD (n=8) and DBD (n=8) porcine hearts.
- All grafts were weaned from CPB with adequate cardiac outputs (≈5.0 vs 4.5 L/min; p=0.14).
- LV contractility (Ees) increased post-transplant; RV Ees was unchanged; no primary graft dysfunction occurred during 2-hour observation.
Methodological Strengths
- Controlled large-animal model including both DCD and DBD donors.
- Direct biventricular pressure-volume loop assessment providing load-independent contractility metrics.
Limitations
- Preclinical animal study with short (2-hour) post-transplant observation.
- Single preservation protocol; no head-to-head comparison with other machine perfusion strategies.
Future Directions: Phase I/II clinical feasibility trials of HOPE in human heart transplantation (including DCD donors), with extended post-implant functional and clinical endpoints.
BACKGROUND: Heart transplantation using standard static cold storage is associated with an increased risk of organ injury if the cold ischemic time exceeds 4-5 hours. The present study investigated an innovative approach using hypothermic oxygenated perfusion (HOPE) to extend preservation time to 24 hours and assessed its impact on post-transplant graft function. METHODS: This study assessed graft efficacy based on a single preservation strategy across two donor types: 1) donation after circulatory death (DCD) (n=8) and 2) donation after brain death (DBD) (n=8), both followed by direct procurement and 24 hours of HOPE before transplantation. After weaning from cardiopulmonary bypass (CPB), biventricular function was assessed using biventricular pressure-volume loops and pulmonary artery catheters during a 2-hour observation period. RESULTS: All included transplantations were successfully weaned from CPB and achieved comparable and adequate cardiac outputs (DCD: 5.0 ± 0.56 L/min, DBD 4.5 ± 0.21 L/min, p=0.14). Both left (LV) and right ventricular (RV) myocardial contractility were preserved; LV end-systole elastance (Ees) was significantly higher after transplantation compared to baseline (p<0.001), whereas RV Ees showed no significant change over time (p=0.08). No primary graft dysfunction occurred during the observation period. CONCLUSION: 24-hours of HOPE preservation ensured preserved graft viability after both DCD and DBD heart transplantation in a porcine model. Our results suggest a potential to significantly extend preservation time in clinical heart transplantation.